GILD — Gilead Sciences Balance Sheet
0.000.00%
- $170.34bn
- $187.56bn
- $29.44bn
Annual balance sheet for Gilead Sciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 6,520 | 6,385 | 7,264 | 9,991 | 7,632 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 4,493 | 4,777 | 4,660 | 4,420 | 4,913 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 14,772 | 14,443 | 16,085 | 19,173 | 18,342 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 5,663 | 5,475 | 5,317 | 5,414 | 5,606 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 67,952 | 63,171 | 62,125 | 58,995 | 59,023 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 11,610 | 11,237 | 11,280 | 12,004 | 11,813 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 46,883 | 41,931 | 39,292 | 39,665 | 36,321 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 21,069 | 21,240 | 22,833 | 19,330 | 22,702 |
| Total Liabilities & Shareholders' Equity | 67,952 | 63,171 | 62,125 | 58,995 | 59,023 |
| Total Common Shares Outstanding |